Dr. Tim A. Richardson, MD
Urology (Urology Physician)
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 1,497
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Urology Physician primary
KS license 04-35760
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ascension Via Christi Hospitals Wichita, Inc. Wichita, KS
- Wesley Medical Center Wichita, KS
- William Newton Hospital Winfield, KS
- Kansas Surgery & Recovery Center Wichita, KS
- Sck Health Arkansas City, KS
Medical groups
- Wichita Urology Group PA (30 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,497
- Services billed
- 25,582
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 10,320 | 69 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 7,141 | 67 |
| Established patient office or other outpatient visit, 30-39 minutes | 856 | 576 |
| Bcg live intravesical instillation, 1 mg | 667 | 12 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 645 | 97 |
| Insertion of needle into vein for collection of blood sample | 269 | 256 |
| New patient office or other outpatient visit, 45-59 minutes | 268 | 268 |
| Manual urinalysis test with examination using microscope, automated | 234 | 208 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 224 | 103 |
| Diagnostic exam of bladder and urethra using an endoscope | 222 | 196 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tamsulosin Hcl Other prescribers in Wichita, KS | 850 |
| Erleada (apalutamide) | 365 |
| Orgovyx (relugolix) | 361 |
| Finasteride Other prescribers in Wichita, KS | 277 |
| Xtandi (enzalutamide) | 242 |
| Nubeqa (darolutamide) | 218 |
| Myrbetriq (mirabegron) Other prescribers in Wichita, KS | 170 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Wichita, KS | 142 |
| Solifenacin Succinate Other prescribers in Wichita, KS | 99 |
| Prednisone Other prescribers in Wichita, KS | 87 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 94 payments worth $57,472 in total to this clinician.
| Janssen Biotech, Inc. | $20,383 |
|---|---|
| Astellas Pharma US Inc | $8,245 |
| Pfizer Inc. | $5,623 |
| Merck Sharp & Dohme LLC | $5,282 |
| Bayer HealthCare Pharmaceuticals Inc. | $4,691 |
| Dendreon Pharmaceuticals LLC | $3,864 |
| Ferring Pharmaceuticals Inc. | $2,850 |
| Immunitybio, Inc. | $2,779 |
| Compensation for services other than consulting (speaking, faculty) | $31,623 |
|---|---|
| Consulting Fee | $19,160 |
| Honoraria | $2,500 |
| Food and Beverage | $2,410 |
| Travel and Lodging | $1,780 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Astellas Pharma US Inc Nov 5, 2025 | Consulting Fee Xtandi · Oncology | $5,000 |
| Merck Sharp & Dohme LLC Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $4,770 |
| Janssen Biotech, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Pfizer Inc. May 20, 2025 | Consulting Fee | $3,050 |
| Astellas Pharma US Inc May 15, 2025 | Consulting Fee Padcev · Oncology | $3,000 |
| Ferring Pharmaceuticals Inc. May 12, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,850 |
| Immunitybio, Inc. Dec 3, 2025 | Honoraria ANKTIVA · Immunotherapy | $2,500 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $1,470 |
All 35 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Dendreon Pharmaceuticals LLC Dec 23, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,400 |
| Merck Sharp & Dohme LLC Dec 17, 2025 | Compensation for services other than consulting (speaking, faculty) KEYTRUDA · ONCOLOGY | $4,770 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Denver, CO · in-kind | $296 |
| Merck Sharp & Dohme LLC Dec 10, 2025 | Travel and Lodging KEYTRUDA · ONCOLOGY · travel to Denver, CO · in-kind | $176 |
| Immunitybio, Inc. Dec 3, 2025 | Honoraria ANKTIVA · Immunotherapy | $2,500 |
| Dendreon Pharmaceuticals LLC Nov 26, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,400 |
| Janssen Scientific Affairs, LLC Nov 24, 2025 | Consulting Fee ERLEADA · Oncology | $1,410 |
| Janssen Pharmaceuticals, Inc Nov 19, 2025 | Consulting Fee | $1,410 |
| Pfizer Inc. Nov 17, 2025 | Consulting Fee | $610 |
| Astellas Pharma US Inc Nov 5, 2025 | Consulting Fee Xtandi · Oncology | $5,000 |
| Janssen Biotech, Inc. Oct 28, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Joplin, MO · in-kind | $1,034 |
| Janssen Biotech, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Oct 13, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Joplin, MO · in-kind | $5.50 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee | $1,220 |
| Pfizer Inc. Sep 2, 2025 | Consulting Fee | $610 |
| Bayer HealthCare Pharmaceuticals Inc. Aug 15, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $1,470 |
| Bayer HealthCare Pharmaceuticals Inc. Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $1,470 |
| Janssen Biotech, Inc. Jul 2, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,110 |
| Janssen Biotech, Inc. May 29, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $694 |
| Janssen Biotech, Inc. May 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $416 |
| Pfizer Inc. May 20, 2025 | Consulting Fee | $3,050 |
| Astellas Pharma US Inc May 15, 2025 | Consulting Fee Padcev · Oncology | $3,000 |
| Ferring Pharmaceuticals Inc. May 12, 2025 | Consulting Fee ADSTILADRIN · ONCOLOGY | $2,850 |
| Janssen Biotech, Inc. Apr 16, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,163 |
| Janssen Biotech, Inc. Apr 16, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Overland Park, KS | $252 |
| Janssen Biotech, Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,110 |
| Janssen Biotech, Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,110 |
| Janssen Biotech, Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,110 |
| Janssen Biotech, Inc. Apr 2, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Omaha, NE · in-kind | $5.50 |
| Janssen Biotech, Inc. Mar 27, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Omaha, NE · in-kind | $5.50 |
| Dendreon Pharmaceuticals LLC Mar 17, 2025 | Compensation for services other than consulting (speaking, faculty) PROVENGE · CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | $1,050 |
| Bayer HealthCare Pharmaceuticals Inc. Mar 15, 2025 | Compensation for services other than consulting (speaking, faculty) Nubeqa · Oncology | $1,470 |
| Janssen Biotech, Inc. Mar 12, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to KANSAS CITY, MO · in-kind | $5.50 |
| Janssen Biotech, Inc. Feb 26, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $555 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 6 companies. The companies reported $1,011,167 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco
AstraZeneca Pharmaceuticals LP - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-…
Janssen Research & Development, LLC - A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasiv…
Merck Sharp & Dohme LLC - A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
Sumitomo Pharma America, Inc. · Completed · NCT05467176 - A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) …
Janssen Research & Development, LLC - A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Ri…
Janssen Research & Development, LLC - A two-part, Phase 1 dose escalation and expansion followed by a randomized, open-label multicenter, Phase 2 study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutam…
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.